

ASX Release

NOVITA SIGNS KEY UK PARTNER SUPPLY AGREEMENT

Highlights

- Supply agreement signed with Edtech Impact, one of the UK's leading school-led marketplaces reaching +90% of schools across the UK,
- Edtech Impact to proactively promote Tali Train to its +180,000 teachers a month using its platform and subscribing to Edtech Impact Guides,
- Edtech Impact and Novita will also partner on specific school leader only events and on the collection of data related to the use of and the social, economic and education impact of Tali Train in the UK school system,
- Data collected will provide a base for potential expansion of the Tali technology into the NHS (National Health Scheme) in the UK and provide a base for expansion into Europe post receipt of CE Mark for Tali Train.
- Tali Train is Effective for Children with Development Disorders as well as Typically Developing Children.

Novita Healthcare Limited (ASX: NHL) (“**Novita**” or the “**Company**”) developer of Tali Train, is pleased to announce it has signed a supply agreement with Edtech Impact (www.edtechimpact.co.uk) founded by the team behind the Innovate My School community.

In collaboration with the joint venture partners YPO and Innovate My School, products on the Edtech Impact platform are seen by more than 180,000 site visitors each month. It undertakes targeted campaigns to teachers who have already expressly opted-in to obtain first access to and use of new technologies such as Tali Train.

Greater than 90% of schools across the UK receive the Edtech Impact Guides that showcase a specific Edtech product with real life impact stories. Tali Train, as a first line or complimentary early childhood intervention for the treatment of inattention, is well placed to benefit from Edtech Impact's reach into UK schoolteacher communities.

Edtech Impact and Novita will also partner on specific school leader only events and on the collection of data related to the use of and the social, economic and education impact of Tali Train in the UK school system. This will provide a base for potential expansion of the Tali technology into the NHS (National Health Scheme) in the UK and provide a base for expansion into Europe post receipt of CE Mark for Tali Train (refer ASX announcement 29th August 2019).

Chairman Comment

“This is a significant step forward for Novita as Edtech Impact specifically targets schools that have already identified the need for tools such as Tali Train. In effect this is a pool of pre-qualified high value sales targets that will assist to compress the sales cycle and potentially drive timely revenue generation for Tali in the UK.”

Tali Train (ARTG Class 1, FDA Class 2) is a scientifically proven game-based training program for 3 – 8-year-old children, focused on treating childhood attention issues. It is delivered via a tablet at home or delivered in a classroom setting at school.

Tali is Effective for Children with Development Disorders as well as Typically Developing Children. It also helps children get “school ready”.

CONTACT

Glenn Smith

Managing Director

Novita Healthcare Ltd

p: 1300 082 013

e: gsmith@novitahealthcare.com.au

Sue MacLeman

Chair

Novita Healthcare Ltd

p: 1300 082 013

e: smacleman@novitahealthcare.com.au

ABOUT EDTECH IMPACT

Edtech Impact (www.edtechimpact.co.uk) is the first school-led marketplace that maps user feedback around educational outcomes, enabling teachers to filter products based on their impact in different school environments.

ABOUT NOVITA

Novita Healthcare Limited (ASX: NHL) is a leading early childhood technology business targeting ATTENTION in children through its breakthrough Tali platform. Tali combines evidence based proprietary algorithms inside a game-based program to assess (Tali Detect) and strengthen (Tali Train) core attention in early childhood (www.talihealth.com).